Literature DB >> 11802109

Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report.

M Shipkova1, V W Armstrong, D Kuypers, F Perner, V Fabrizi, H Holzer, E Wieland, M Oellerich.   

Abstract

Mycophenolic acid (MPA) concentrations are lower in transplant recipients receiving mycophenolate mofetil (MMF) and cyclosporine compared with MMF with tacrolimus. It is not clear whether this is due to an effect of cyclosporin or tacrolimus on MPA pharmacokinetics. To study this effect, kidney transplant recipients with deteriorating renal function (n = 5) receiving cyclosporin and steroids were given mycophenolate mofetil over 4 weeks during a run-in phase (1 g/d in week 1, 1.5 g/d in week 2, 2 g/d starting from week 3). From week 5 the cyclosporin dose was reduced, and it was completely withdrawn at week 10. Creatinine, MPA, and MPA glucuronide metabolites (MPAG, AcMPAG) were determined before (week 4) and after (week 11 and week 32) cyclosporin was withdrawn. Cyclosporin withdrawal was associated with increased MPA areas under the curve (AUCs) and predose concentrations in four of the five patients. In contrast, MPAG and AcMPAG AUCs as well as predose MPAG concentrations significantly decreased. Six months after cyclosporin withdrawal, MPA AUC and predose values tended to return to initial values, whereas metabolite concentrations remained low. Cyclosporin discontinuation caused an acute increase in MPA exposure and a concomitant reduction in metabolite concentrations. The results are consistent with the hypothesis that cyclosporin attenuates the enterohepatic recirculation of MPAG/MPA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11802109     DOI: 10.1097/00007691-200112000-00020

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Authors:  Dirk R Kuypers; Henrik Ekberg; Josep Grinyó; Björn Nashan; Flavio Vincenti; Paul Snell; Richard D Mamelok; Rene M Bouw
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Authors:  Matthias Behrend; Felix Braun
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

Authors:  Gilbert J Burckart; William D Figg; Maria M Brooks; Dionna J Green; Sarah M Troutman; Robert Ferrell; Richard Chinnock; Charles Canter; Linda Addonizio; Daniel Bernstein; James K Kirklin; David Naftel; Douglas K Price; Tristan M Sissung; Diana M Girnita; Adriana Zeevi; Steven A Webber
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

6.  Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.

Authors:  Claudia Sommerer; Sandra Müller-Krebs; Matthias Schaier; Petra Glander; Klemens Budde; Vedat Schwenger; Gerd Mikus; Martin Zeier
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

7.  A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.

Authors:  Aurélie Prémaud; Jean Debord; Annick Rousseau; Yannick Le Meur; Olivier Toupance; Yvon Lebranchu; Guillaume Hoizey; Chantal Le Guellec; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.

Authors:  Zheng Jiao; Jian-Yong Zhong; Ming Zhang; Xiao-Jin Shi; Yun-Qiu Yu; Wei-Yue Lu
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

9.  Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.

Authors:  Jeong M Park; Kathleen D Lake; Diane M Cibrik
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

Review 10.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.